Skip to main content
. 2022 Nov 11;13:1034253. doi: 10.3389/fimmu.2022.1034253

Figure 4.

Figure 4

The pooled PR (A), ORR (B), SDR (C), and DCR (D) in patients with R/R indolent B-NHL receiving copanlisib monotherapy were significantly higher than those in patients with R/R aggressive B-NHL receiving copanlisib monotherapy, while result for pooled PDR (E) was reversed between the two groups.